|
Drug firms and cancer Lucrative lifesavers 医药公司和癌症 利润丰厚的救星 The hopes and perils of betting on cancertreatments 癌症治疗的希望和风险 NEW weapons are emerging in the war on cancer. 在对癌症的战争中不断有新武器出现。 That is good news not just for patients but also fordrug companies. 这不仅对病人是好消息，对制药公司也是好消息。 The biggest ones, faced with falling sales as their existing medicines go off-patent, areinvesting in smaller firms with promising cancer treatments under development, hoping tosecure the next blockbuster. 最先有药物面临着销售下滑，失去专利保护，最重要的是投资于正在开发有前途的癌症治疗方法的小公司来确保拥有下一个重磅炸弹。 On August 25th Amgen, the world s biggest biotechnology company by sales, said it wouldpay $10.4 billion for another American firm, Onyx. 8月25日世界上最大的生物技术公司安进表示，它将支付104亿美元收购Onyx公司。 The target firm s crown jewel is Kyprolis, a treatment for multiple myeloma, a type of bloodcancer. 该公司拥有的药物Kyprolis能治疗多发性骨髓瘤，一种类型的血癌。 | 
